In the current guidelines of the European Society of Cardiology, it is recommended to measure non-HDL cholesterol and apolipoprotein B for cardiovascular risk evaluation instead of LDL cholesterol, as values can be inaccurate, e.g., in patients with diabetes, high triglyceride [35] and analytical issues to measure LDL can occure. This evidence concerns the gene APOB and diabetes mellitus.